Shots:

• QIAGEN launches its therascreen BRAF V600E RGQ PCR Kit as a CDx to Pfizer's Braftovi (encorafenib) in combination with Lilly’s Erbitux (cetuximab) for the treatment of patients with m-CRC with a BRAF V600E mutation- as detected by an FDA-approved test- after prior therapy
• The therascreen BRAF V600E kit runs on QIAGEN’s Rotor-Gene Q MDx and detects V600E mutation which helps to identify patients eligible for treatment with the combination regimen
• The therascreen BRAF V600E Kit will be available to accelerate the availability of innovations in precision medicine and is QIAGEN’s first CDx to obtain FDA approval for the detection of a mutation in the BRAF gene

­ Ref:  PRNewswire | Image: QIAGEN